CSL Limited (ASX:CSL) FY26 Results: Revenue Steady at $15.8 Billion Amid Transformation Program

Sonal Goyal

17 September 2026 03:39 AM AEST

CSL Limited (ASX:CSL) FY26 Results: Revenue Steady at $15.8 Billion Amid Transformation Program

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

CSL reported FY26 Revenue of $15.8 billion, a 1% decline at constant currency, for the year ended 30 June 2026
Underlying NPATA for FY26 was $3.1 billion, down 2% at constant currency, while reported NPAT was a net loss of $2.6 billion
CSL Behring revenue was $11.4 billion, CSL Seqirus revenue was $2.0 billion and CSL Vifor revenue was $2.4 billion for the period
The company completed an approximately A$1 billion share buy-back and maintained its Dividend during the reporting period

CSL Limited (ASX:CSL; USOTC: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia, operating across plasma-derived therapies, vaccines and specialty biopharmaceutical products. This article outlines the company's recent full-year financial results, its core Business operations, sector context and the developments shareholders are monitoring heading into the next financial year.

The share price was AUD 177.56 during the Trading session on 17 September 2026. The stock moved up by 1.81% during the trading session on 17 September 2026.

Company Business

CSL Limited operates through three core segments. CSL Behring manufactures, markets and distributes plasma-derived products, gene therapies and recombinant proteins, with immunoglobulin therapies forming its largest product category. CSL Seqirus manufactures and distributes predominantly influenza-related vaccines and provides Pandemic preparedness services to governments. CSL Vifor manufactures and markets products focused on iron deficiency and nephrology. The company's CSL Plasma division operates a plasma collection network of approximately 325 centres across the United States, Europe and China, underpinning the raw material Supply for its therapies. CSL's operations span Australia, the United States, Germany, the United Kingdom, Switzerland and China, including Hong Kong, with products such as Respreeza, Zemaira, HAEGARDA, Kcentra, Evogam, ANDEMBRY and HEMGENIX sold in global markets.

Sector Context

The global biotechnology and plasma therapeutics sector continues to be shaped by patient Demand for immunoglobulin and specialty therapies, alongside evolving reimbursement frameworks in major markets such as the United States. Companies in this sector face regulatory oversight from bodies including the U.S. Food and Drug Administration, the Therapeutic Goods Administration in Australia and equivalent agencies in Europe. Policy settings such as Medicare Part D reforms in the United States and government cost-containment measures in markets including China have been cited by companies in the sector as factors influencing revenue trends. Seasonal Vaccine demand and government pandemic-preparedness contracts also remain relevant to companies operating influenza vaccine franchises.

Recent Developments

CSL announced its FY26 full year results on 18 August 2026 for the twelve months ended 30 June 2026, describing the period as a reset year involving strategic transformation initiatives. The company had earlier provided an Interim CEO 90-Day Review and Financial Update on 11 May 2026, in which Interim Chief Executive Officer and Managing Director Gordon Naylor outlined a revised FY26 outlook following a review of the business. During the year, the company progressed its transformation program, realising $176 million in cost savings, and invested in growth initiatives including a strategic collaboration with Dutch biotechnology company VarmX. CSL also announced plans to invest approximately $1.5 billion to expand its United States plasma Manufacturing capacity.

Financial Performance

For the full year ended 30 June 2026, CSL reported total revenue of $15.8 billion, a 1% decline at constant currency. Underlying NPATA was $3.1 billion, down 2% at constant currency, while underlying NPAT excluding one-off restructuring costs and impairments was $2.8 billion, down 3%. Reported NPAT was a net loss of $2.6 billion, reflecting one-off pre-tax restructuring costs of $0.8 billion and Impairment and related costs of $7.1 billion. Cash Flow from operations was $3.5 billion, down 1% year-on-year. By segment, CSL Behring revenue was $11.4 billion, down 1%; CSL Seqirus revenue was $2.0 billion, down 8%; and CSL Vifor revenue was $2.4 billion, up 3%. The company completed an approximately A$1 billion share buy-back during the period and maintained its dividend.

Risks to Consider

CSL's operations are subject to risks including changes in government reimbursement policy, such as Medicare Part D reforms in the United States and cost-containment measures in China, which the company has identified as factors affecting segment revenue. Execution risk associated with the ongoing transformation program, including the realisation of targeted cost savings, remains relevant. Competitive pressure in categories such as iron therapies and certain plasma products, funding requirements for Capital Investment in manufacturing capacity, and the impact of non-cash impairment charges on reported Earnings are additional factors noted in the company's disclosures. Foreign exchange movements also affect reported results given the company's global revenue base.

What to Watch Next

CSL's Annual General Meeting is scheduled to be held with a Notice of Meeting to be released to shareholders, with disclosure obligations requiring this at least 30 business days before the event. The company's financial calendar includes its half-year results and Interim Dividend announcement in February 2027. Progress on the transformation program, further updates on the United States plasma manufacturing expansion, and the trajectory of immunoglobulin and albumin revenue growth into FY27 are among the operational items flagged by management for the year ahead.

Key Insights

CSL's FY26 results reflect a period the company has characterised as a reset year, combining steady underlying operating performance with substantial non-cash impairment and restructuring charges. Segment performance varied, with CSL Vifor returning to growth while CSL Seqirus revenue declined. The company's transformation program, plasma manufacturing investment and product pipeline, including ANDEMBRY and HEMGENIX, are among the factors shareholders may continue to monitor alongside upcoming financial disclosures.

FAQs

Q: What are CSL Limited's main business segments?

A:CSL operates through CSL Behring, which focuses on plasma-derived therapies, gene therapies and recombinant proteins; CSL Seqirus, which focuses on influenza vaccines and pandemic services; and CSL Vifor, which focuses on iron deficiency and nephrology products.

Q: What was CSL's revenue for FY26?

A:CSL reported total revenue of $15.8 billion for the twelve months ended 30 June 2026, a 1% decline at constant currency.

Q: Why did CSL report a net loss for FY26?

A:The reported net loss of $2.6 billion reflected one-off pre-tax restructuring costs of $0.8 billion and impairment and related costs of $7.1 billion recognised during the year.

Q: Where does CSL operate?

A:CSL operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China, including Hong Kong, with a plasma collection network of approximately 325 centres across the United States, Europe and China.

Q: What is CSL's ticker code?

A:CSL Limited trades on the Australian Securities Exchange under the code CSL, and on the U.S. over-the-counter market under the code CSLLY.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.